CD4-positive diffuse large B-cell lymphoma: A variant with aggressive clinical potential

CD4 expression is rare in diffuse large B-cell lymphoma (DLBCL), with 4 previously reported cases. Its significance is uncertain. We report five patients with CD4(+) DLBCL and one CD4(+) primary mediastinal large B-cell lymphoma. Cases were identified by searching the electronic database of the depa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussaini, Mohammad O, Kreisel, Friederike H, Hassan, Anjum, Nguyen, TuDung T, Frater, John L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Diagnostic Advances
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031925/
https://www.ncbi.nlm.nih.gov/pubmed/27679780
http://dx.doi.org/10.5662/wjm.v6.i3.181
Descripción
Sumario:CD4 expression is rare in diffuse large B-cell lymphoma (DLBCL), with 4 previously reported cases. Its significance is uncertain. We report five patients with CD4(+) DLBCL and one CD4(+) primary mediastinal large B-cell lymphoma. Cases were identified by searching the electronic database of the department; each was reviewed. Average age was 56 years. Neoplastic cells expressed CD20 (5/6 tested cases). BCL2/BCL6 expression were seen in 3/3 tested cases, suggesting a germinal center origin. Additionally, expression of T-cell antigens CD2 and CD5 was noted in 2/2 and CD7 in 1/1 tested case. CD3 was negative in all. Lymph nodes were commonly involved (67%). Patients received chemotherapy +/- radiation (6/6) and bone marrow transplant (2/6). Average survival was 44.2 mo. CD4 expression in DLBCL raises questions of lineage commitment. CD4(+) DLBCL is rare; care should be exercised not to diagnose these as T-cell lymphomas. A subset behaves aggressively.

Ejemplares similares